A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease

NCT00399477 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson's Disease

Interventions

DRUG: rasagiline mesylate
DRUG: Rasagiline mesylate plus Mirapex
DRUG: Rasagiline mesylate with Levodopa
DRUG: Rasagiline mesylate with Requip

Sponsor

Teva Neuroscience, Inc.